Li Xinwei, Xiong Wei, Xiong Zhiyong, Zhang Xiaoping
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Institute of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cell Dev Biol. 2025 Jan 20;13:1521151. doi: 10.3389/fcell.2025.1521151. eCollection 2025.
Renal cell carcinoma is a common type of cancer, with approximately 30% of patients potentially developing metastatic disease. Some patients with metastatic renal cell carcinoma are found in advanced stages, so the 5-year survival rate for metastatic renal cell carcinoma is only 14%. Currently, there are several drugs available for patients with metastatic renal cell carcinoma, and their overall survival can be extended to nearly 5 years. However, the sensitivity and efficacy of the treatment are still unsatisfactory. New targets and drugs to improve patient prognosis are urgently needed, but these are closely linked to the molecular mechanisms of renal cell carcinoma metastasis. In this review, we present the definition and common molecular mechanisms of metastatic renal cell carcinoma and provide new insights on their potential link to targeted therapies, which may enlighten scientists to develop future targeted therapeutic agents to improve the prognosis of patients with metastatic renal cell carcinoma.
肾细胞癌是一种常见的癌症类型，约30%的患者可能发生转移性疾病。一些转移性肾细胞癌患者在晚期被发现，因此转移性肾细胞癌的5年生存率仅为14%。目前，有几种药物可供转移性肾细胞癌患者使用，其总生存期可延长至近5年。然而，治疗的敏感性和疗效仍不尽人意。迫切需要新的靶点和药物来改善患者预后，但这些与肾细胞癌转移的分子机制密切相关。在这篇综述中，我们阐述了转移性肾细胞癌的定义和常见分子机制，并对其与靶向治疗的潜在联系提供了新的见解，这可能启发科学家开发未来的靶向治疗药物，以改善转移性肾细胞癌患者的预后。
